Third Opinion Trial Synopsis
Doctors are testing a new treatment for people with certain types of blood cancers. This treatment uses special cells called natural killer (NK) cells, which can kill cancer cells in the body. First, patients will get chemotherapy and a transplant of umbilical cord blood. Then, doctors will use personalized NK cells to help fight the cancer. The doctors will also select cord blood based on certain genes that match each patient. The hope is that this new treatment can help more people beat their cancer and have fewer side effects from the transplant.

Trial Summary
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.